If it has been stored at room temperature already (which is acceptable for certain formulations for limited periods), this step becomes less critical
Phase 3 added a dysesthesia signal that did not appear at the same rate in earlier studies
From there, your provider will likely increase the dose in 2.5 mg increments every four weeks as needed, climbing through 5 mg , 7.5 mg , 10 mg , 12.5 mg , and up to a maximum of 15 mg per week
(MP4 3429 kb) Studies investigating the mechanism of action of GLP-1RA therapy for causing weight loss provide evidence that GLP-1RA treatment is associated with reductions in appetite and hunger, lower preference for energy-dense foods, alteration in food reward pathways, decrease in food cravings, and improvement in eating control (Table 2) [25, 26, 33, 34]
Retatrutide's bioavailability via subcutaneous injection is approximately 95% per Phase 1 pharmacokinetic data (Coskun et al., 2022), meaning very little drug is lost at the injection site regardless of which approved location you choose